Back

Common variation at the LRRK2 locus is associated with survival in the primary tauopathy progressive supranuclear palsy

Jabbari, E.; Tan, M. M. X.; Reynolds, R. H.; Mok, K. Y.; Ferrari, R.; Murphy, D. P.; Valentino, R. R.; Ross, O. A.; Dickson, D. W.; Al-Sarraj, S.; Gentleman, S. M.; Allinson, K. S. J.; Jaunmuktane, Z.; Holton, J. L.; Revesz, T.; Warner, T. T.; Lees, A. J.; Cookson, M. R.; Gibbs, J. R.; Ding, J.; Chia, R.; Traynor, B. J.; Scholz, S. W.; Pantelyat, A.; Viollet, C.; Dalgard, C. L.; Pletnikova, O.; Troncoso, J. C.; Boxer, A. L.; Respondek, G.; Hoglinger, G. U.; Burn, D. J.; Pavese, N.; Gerhard, A.; Kobylecki, C.; Leigh, P. N.; Church, A.; Hu, M. T. M.; Rowe, J. B.; Ryten, M.; Hardy, J.; Shoai, M.;

2020-02-04 genetics
10.1101/2020.02.04.932335 bioRxiv
Show abstract

The genetic basis of variation in the rate of disease progression of primary tauopathies has not been determined. In two independent progressive supranuclear palsy cohorts, we show that common variation at the LRRK2 locus determines survival from motor symptom onset to death, possibly through regulation of gene expression. This links together genetic risk in alpha-synuclein and tau disorders, and suggests that modulation of proteostasis and neuro-inflammation by LRRK2 inhibitors may have a therapeutic role across disorders.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.